Production (Stage)
D
Aldeyra Therapeutics, Inc. ALDX
$2.22 -$0.03-1.33% NASDAQ
Recommendation
Prev Close
$2.22
Volume
705,572
Avg Vol (90D)
1,367,170
Market Cap
$132.97M
Dividend & Yield
--
52-Week Range
$1.14 - $7.20
P/E (TTM)
--
EPS (TTM)
-$0.9686
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Q3 Earnings Forecast for ALDX Issued By Leerink Partnrs
5/24/2025 - MarketBeat
Aldeyra Therapeutics (NASDAQ:ALDX) Upgraded at Wall Street Zen
5/24/2025 - Ticker Report
Aldeyra Therapeutics (NASDAQ:ALDX) Raised to "Sell" at StockNews.com
5/23/2025 - MarketBeat
HC Wainwright Has Strong Estimate for ALDX FY2029 Earnings
5/22/2025 - MarketBeat
Aldeyra Therapeutics' (ALDX) "Buy" Rating Reiterated at HC Wainwright
5/21/2025 - MarketBeat
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
5/18/2025 - Globe Newswire
Aldeyra Therapeutics, Inc (NASDAQ:ALDX) Shares Purchased by Dimensional Fund Advisors LP
5/16/2025 - MarketBeat
Bragar Eagel & Squire, P.C. Is Investigating Organon, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
5/15/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Aldeyra Therapeutics, Inc. ALDX
5/13/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
5/12/2025 - PR Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
5/9/2025 - Globe Newswire
Bragar Eagel & Squire, P.C. Is Investigating RobinHood, Aldeyra, Landstar, and ICU Medical and Encourages Investors to Contact the Firm
5/8/2025 - Globe Newswire
Aldeyra Therapeutics Drops To US$2.10, Yet Insiders May Have Sold Too Early
5/7/2025 - Simply Wall St
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by ...
5/7/2025 - GuruFocus
ALDX SECURITIES UPDATE: Aldeyra Therapeutics Investors with Losses may have been affected by Securities Violations Contact BFA Law (NASDAQ:ALDX)
5/7/2025 - Globe Newswire
Aldeyra Therapeutics, Inc. (ALDX) Faces Scrutiny After Stock Drops 70% On FDA's Reproxalap Complete Response Letter Hagens Berman
5/6/2025 - Globe Newswire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
5/6/2025 - PR Newswire
Invesco Ltd. Cuts Holdings in Aldeyra Therapeutics, Inc (NASDAQ:ALDX)
5/6/2025 - MarketBeat
aldeyra posts 1 hit 1 miss twice rejected dry eye drug plans fda filing
5/6/2025 - FierceBiotech.com - Biotech
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of ...
5/5/2025 - GuruFocus
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of ...
5/5/2025 - GuruFocus
Aldeyra Therapeutics Achieves Primary Endpoint in Phase 3 Dry Eye Disease Chamber Trial of Reproxalap and Plans NDA Resubmission
5/5/2025 - Business Wire
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from ...
5/5/2025 - GuruFocus
Aldeyra Therapeutics Schedules Conference Call and Webcast to Announce Topline Results from Phase 3 Dry Eye Disease Clinical Trials of Reproxalap
5/5/2025 - Business Wire
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX
5/5/2025 - Globe Newswire
Income Statement
Total Revenue (TTM)
--
EBITDA (TTM)
-$60.90M
EBIT (TTM)
-$61.15M
Net Income (TTM)
-$57.70M
Balance Sheet
Total Assets (Q)
$93.20M
Total Debt (Q)
$15.57M
Total Liabilities (Q)
$29.60M
Book Value Per Share (Q)
$1.06
Cash Flow
Cash from Operations (TTM)
-$45.71M
Cash from Investing (TTM)
-$7.25M
Cash from Financing (TTM)
$813.20K
Net Change in Cash (TTM)
-$52.14M
Filings
Filing Date
Wednesday, May 14, 2025
Period Date
Monday, March 31, 2025
Next Filing
Beginning of August (est)
Price History
Loading...
Beta
2.71
7-Day Total Return
2.78%
30-Day Total Return
16.23%
60-Day Total Return
-56.56%
90-Day Total Return
-55.82%
Year to Date Total Return
-57.47%
1-Year Total Return
-43.22%
2-Year Total Return
-76.90%
3-Year Total Return
-17.47%
5-Year Total Return
-45.99%
52-week Low
Apr 03, 2025 - $1.14
52-week High
Mar 12, 2025 - $7.20
Valuation
Market Cap
$132.97M - Micro Cap
Enterprise Value
$58.48M
Price/Sales (TTM)
--
Price/Book (Q)
2.10
Dividends and Shares
Shares Outstanding
59.89M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.aldeyra.com
Phone Number
781 761 4904
Address
131 Hartwell Avenue
Lexington, MA 02421
Country
United States
Year Founded
2004
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Aldeyra Therapeutics, Inc., a biotechnology company, discovers and develops therapies designed to treat immune-mediated and metabolic diseases. Its lead product candidate is reproxalap, a... more
NASDAQ 05/23/2025 4:00PM Eastern Quotes delayed